Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects

Trial Profile

A Phase 1, Open-Label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ASLAN004 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs ASLAN-004 (Primary) ; ASLAN-004 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; First in man
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 17 Oct 2018 According to an ASLAN Pharmaceuticals media release, the company today announced the enrolment of the first subject and the single ascending dose study is expected to complete in the first half of 2019.
    • 17 Oct 2018 Status changed from planning to recruiting, according to an ASLAN Pharmaceuticals media release.
    • 06 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top